Analysis of the data obtained from the first 381 patients included in the AURORA research programme have revealed important molecular and clinical features that shed light on metastatic breast cancer (MBC) and its evolution. The detailed results were published on June 28th in Cancer Discovery, a journal of the American Association for Cancer Research.
AURORA is an international academic research programme based on molecular screening and dedicated to improving the understanding of metastatic breast cancer. Its unique large collection of matched primary and metastatic tumour samples, obtained from patients either upon diagnosis of metastatic disease or after one line of treatment, and high-quality clinical data allow researchers to study the molecular changes that occur when breast cancer first starts to spread, and throughout its evolution.
So far, researchers have identified molecular changes that are more common in metastatic samples. These include mutations in driver genes (in 10% of the samples) and in copy number variations (in 30% of samples). These findings could lead to the future development of new treatment strategies for patients with MBC.
Full article: AURORA study: towards a better understanding of the molecular changes driving metastatic breast cancer (ibbl.lu)
for articles/videos/studies
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.
